Novo Nordisk filed for FDA approval of CagriSema in early 2026, with a review decision expected later this year
This dual-compound approach targets multiple metabolic pathways simultaneously, which some patients find more effective than single-agent therapy
As a result, its not uncommon to experience feelings of weakness and extreme daytime sleepiness
Impulse Control and Addiction: Some preclinical studies have even suggested that the melanocortin system, particularly via the MC4R, may play a role in addictive behaviors, opening yet another avenue for investigation with MT-2
Injectable peptide trends are exploding online, but many products promoted on social platforms are unapproved, poorly regulated, and sometimes contaminated/mislabeled, with regulators actively trying to suppress misleading advertising